Figure 5.

Changes of immunoreactivity of GFAs and TAs parallel the progression of the AGD stage in the frontal cortex (A) and putamen (B) in AGD cases. About 35% of cases with AGD stage I had GFAs labeled by several anti‐tau antibodies in the frontal cortex and putamen. Neither Gallyas‐ nor p62‐positive lesions were noted in these cases. Gallyas‐positive TAs were first noted in cases with AGD stage II, and the proportion of AGD cases with TAs increased with AGD stage. p62‐positive GFAs were first noted in cases with AGD stage III. In this study, when an astrocytic lesion had Gallyas‐positive glial threads, we operationally regarded it as a TA irrespective of the quantity of Gallyas‐positive threads.